Practo’s Healthcare Marketplace Business Model
Industry and Competitive Context
India’s digital health sector grew substantially over the past decade, driven by low smartphone penetration costs, the COVID-19 pandemic’s acceleration of telemedicine adoption, and a historically fragmented, under-digitized healthcare delivery system dominated by small independent clinics and nursing homes. This fragmentation created an opening for intermediaries that could aggregate patient demand and provider supply on a single platform, a classic two-sided marketplace structure.
Practo, founded in Bangalore in 2008 by Shashank ND and Abhinav Lal, positioned itself at the intersection of two distinct but related markets: a consumer-facing discovery and booking layer (helping patients find doctors, book appointments, consult online, order medicines, and book diagnostic tests) and a business-facing software layer (practice management tools sold to doctors, clinics, and hospitals). This dual structure is significant from a strategy standpoint because it combines a transaction marketplace with an enterprise SaaS business inside the same company, a combination that shapes both its revenue model and its competitive set.
Practo’s documented competitors in the Indian digital health space include Lybrate, MediBuddy, and Healthians. The broader digital health category in India also includes e-pharmacy, online diagnostics, and teleconsultation players, reflecting a market where multiple specialized and multi-service platforms coexist rather than a single dominant marketplace.
Business Situation and Evolution
Practo began as a doctor and clinic listing and discovery platform. It subsequently built Practo Ray, a cloud-based practice management software product for clinics and hospitals, and expanded over time into online consultations, medicine delivery, diagnostic test booking, and health insurance distribution. This progression reflects a strategic move from a single-sided information service (doctor listings) toward a multi-product platform spanning discovery, transactions, and enterprise software.
The company raised a $90 million Series C round in 2015, led by Tencent, followed by a $55 million Series D round in January 2017, also led by Tencent, with participation from Sequoia, Matrix Partners, Capital G (then Google Capital), Altimeter Capital, Sofina, Russia’s Ru-Net, Japan’s RSI Fund (backed by Recruit), and New York-based Thrive Capital. At the time of the Series D round, Practo reported operating in India and four other countries (the Philippines, Indonesia, Singapore, and Brazil), with its software serving customers in fifteen countries, and reported approximately 45 million appointments annually across 200,000 practitioners, 10,000 hospitals, and 5,000 diagnostic centers on its platform. Cumulative funding at that point was reported at approximately 180 million US dollars.
In April 2017, Practo reduced its workforce by approximately 150 employees, roughly 10 percent of its headcount, during its annual appraisal cycle. In April 2023, the company laid off 41 employees, concentrated in its engineering department, which was publicly attributed to performance-related reasons.
On the financial side, Practo’s FY23 operating EBITDA loss was reported at Rs 99.4 crore. In FY24 (year ended March 2024), the company reported gross merchandise value (GMV) surpassing Rs 3,500 crore, operating revenue of Rs 240 crore (up 22 percent year-on-year), and an operating EBITDA loss narrowed by 82 percent to Rs 17 crore. The company also reported that its contribution margin improved from negative 1 percent in FY22 to 40 percent in FY24, and that its core India business grew at a 68 percent compound annual growth rate between FY22 and FY24. By this stage, Practo reported serving over 54 million patients across 642 cities and having conducted more than 600 hospital audits in the preceding fiscal year.
In FY25, Practo reported its first full year of operating profitability, with operating EBITDA of Rs 15 crore on revenue of Rs 234 crore, and stated it had delivered six consecutive profitable quarters. It reported serving more than 5 crore patients across 640 cities, with over 5 lakh verified doctors and a hospital network exceeding 1.5 lakh listings, a year-on-year network growth figure of 180 percent as stated by the company. It also reported operating 40 co-branded dermatology clinics, having audited more than 1,000 healthcare establishments, and having processed over 4 crore clinical data points.
Strategic Objective
Based on public statements, Practo’s documented strategic priorities during this period centered on two goals: achieving sustainable unit economics and profitability after a prolonged period of EBITDA losses, and preparing the company for a public listing. The company’s FY23 annual report first referenced listing plans, and its FY25 annual letter stated that the company had “begun preparing to go public.” In October 2023, co-founder Abhinav Lal told Mint that Practo was 12 to 18 months away from a public listing.
Business Model Architecture
Practo’s marketplace architecture operates on two linked revenue streams rather than a single mechanism. The first is practice management software, led by Practo Ray, sold to doctors, clinics, and hospitals as a subscription-based tool that digitizes appointment scheduling, patient records, and clinic operations. The second is the consumer-facing marketplace, through which Practo earns from transactions tied to doctor discovery, online consultations, medicine ordering, and diagnostic test bookings.
This structure allows Practo to use its enterprise software relationships with providers as a channel for patient acquisition and supply-side liquidity on its marketplace, while using its consumer traffic as a value proposition to sell software and visibility tools to providers. From a platform economics perspective, this is a documented strategy of using one side of a two-sided market (software-enabled providers) to deepen defensibility and data assets that support the other side (patient transactions), rather than operating the discovery marketplace and the SaaS business as fully separate lines.
The shift in reported metrics between FY22 and FY24, specifically the swing in contribution margin from negative 1 percent to 40 percent, indicates a period of business model rationalization, in which Practo appears to have reduced the intensity of low-margin or subsidized activity in favor of higher-margin verified transactions and software revenue. No public source specifies which product lines were scaled back or expanded to produce this shift, so this case study does not attribute it to specific product decisions beyond what the company has disclosed.
Positioning and Market Insight
Practo’s consumer positioning rests on verification and trust signals rather than price competition. The company has publicly described conducting facility audits, doctor credential checks, a merit-based provider scoring system, and patient reviews as mechanisms to build trust in a market where patients historically had limited structured information to evaluate healthcare providers. The scale of verification activity disclosed by the company, including over 600 hospital audits in FY24 and over 1,000 healthcare establishment audits by FY25, indicates that verification infrastructure was treated as a core, measurable investment area rather than a peripheral trust-building exercise.
This positioning addresses a structural information asymmetry in Indian healthcare: patients typically lack access to standardized, comparable data on provider quality, and providers historically lacked digital tools to manage patient relationships and operations. Practo’s model monetizes the resolution of both sides of this asymmetry simultaneously, which is consistent with platform strategy literature on two-sided markets, where value is created by reducing search and trust costs for one side while providing operational tooling and demand access to the other.
Business and Brand Outcomes
The documented outcomes of Practo’s business model evolution are primarily financial and operational rather than brand-metric based, since no verified data exists on brand awareness, favorability, or other classic brand health indicators. The company’s own disclosed outcomes include revenue growth from Rs 240 crore in FY24 to a reported Rs 234 crore in FY25 (a marginal year-on-year decline in operating revenue despite the shift to full-year profitability), an operating EBITDA improvement from a loss of Rs 17 crore in FY24 to a profit of Rs 15 crore in FY25, and a GMV figure reported at approximately Rs 3,500 crore in both FY24 and FY25 disclosures.
The company also reported scale metrics including more than 5 crore patients served, more than 5 lakh verified doctors, and a hospital network exceeding 1.5 lakh listings by FY25. These figures, as with all metrics in this case study, are drawn from company disclosures reported in business press coverage and have not been independently audited in the sources reviewed here.
Strategic Implications
Several interpretive observations can be drawn directly from the documented record, without introducing assumptions beyond what has been publicly disclosed.
First, Practo’s path to profitability took more than a decade and a half from founding, and was accompanied by at least two significant workforce reductions, in 2017 and 2023, each coinciding with periods when the company was adjusting its cost structure. This suggests that achieving positive unit economics in a healthcare marketplace model, which combines asset-light transaction revenue with higher-touch enterprise software sales and offline verification processes, required sustained cost discipline over an extended period rather than a rapid path to scale profitability.
Second, the dual revenue structure, combining provider-facing SaaS with consumer-facing marketplace transactions, appears to have provided Practo with a defensibility mechanism distinct from pure consumer marketplaces, since provider software adoption creates switching costs and data lock-in that a discovery-only platform would not have. The disclosed margin improvement between FY22 and FY24 is consistent with, though not proof of, this software layer contributing increasingly to overall business quality.
Third, the company’s stated preparation for a public listing, first referenced in its FY23 annual report, occurred only after it had demonstrated several consecutive quarters of profitability, indicating that Practo’s own public narrative links IPO readiness to profitability milestones rather than growth metrics alone. This is a documented sequencing choice by the company, consistent with broader shifts in Indian startup capital markets after 2022, where profitability became a more prominent listing criterion for technology companies generally, independent of any speculation about Practo’s internal reasoning.
Fourth, the absence of any verified public information on Practo’s consumer marketing or media strategy, despite extensive disclosure on financial and operational metrics, suggests that the company’s public communications during this period were oriented toward investors and the business press rather than toward consumer brand storytelling, a pattern more typical of enterprise and marketplace platforms nearing a potential listing than of consumer brands running visible mass-market campaigns.
Discussion Questions
How does combining an enterprise SaaS revenue stream with a consumer marketplace transaction model change the defensibility and unit economics of a healthcare platform compared to a marketplace-only competitor?
What risks does a two-sided healthcare marketplace face when verification and trust-building activities, such as facility audits and credential checks, are central to its value proposition but costly to scale?
Why might a company choose to disclose detailed financial and scale metrics publicly years before an actual IPO filing, and what signaling effect might this have on competitors, employees, and potential investors?
Given that Practo’s revenue declined slightly from FY24 to FY25 even as EBITDA turned positive, what trade-offs between growth and profitability does this pattern suggest, and how should a marketplace balance these two priorities ahead of a public listing?
In a market with several specialized competitors (such as pure e-pharmacy, pure diagnostics, or pure teleconsultation players), what are the strategic advantages and disadvantages of Practo’s multi-service, full-stack approach to healthcare marketplace design?
Comments